Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04814368 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT04814368 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 23 participants.
The verdict
NCT04814368, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The study was established to show safety and efficacy of canakinumab and LNA043 in patients with knee osteoarthritis (OA).
Interventions
- BIOLOGICAL LNA043
- BIOLOGICAL canakinumab
- OTHER Placebo to canakinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04814368
The ClinicalTrials.gov registry entry for NCT04814368 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LNA043 is the first listed.
NCT04814368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04814368 about?
NCT04814368 is a clinical study titled "A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)". The study was established to show safety and efficacy of canakinumab and LNA043 in patients with knee osteoarthritis (OA).
What is the current status of trial NCT04814368?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2021-08-27. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT04814368?
The interventions under investigation include: LNA043 (BIOLOGICAL), canakinumab (BIOLOGICAL), Placebo to canakinumab (OTHER).
Who is sponsoring clinical trial NCT04814368?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.